Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 16/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.59 |
| ▸ | HPGD | P15428 | 5/20 | 0.59 |
| ▸ | TP53 | P04637 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 5/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RORC | P51449 | 1/20 | 0.45 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.45 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4941715 | 1.00 | MAPT (0.59) | MAPTKDM4EHPGDTP53ALDH1A1 | |
| SCHEMBL4941684 | 0.86 | NPSR1 (0.51) | MAPTKDM4EHPGDALDH1A1NPSR1 | |
| SCHEMBL4941687 | 0.86 | NPSR1 (0.51) | MAPTKDM4EHPGDALDH1A1NPSR1 | |
| SCHEMBL4943201 | 0.85 | MAPT (0.58) | MAPTKDM4EHPGDTP53ALDH1A1 | |
| SCHEMBL4942757 | 0.85 | MAPT (0.58) | MAPTKDM4EHPGDTP53ALDH1A1 | |
| SCHEMBL4942761 | 0.85 | MAPT (0.58) | MAPTKDM4EHPGDTP53ALDH1A1 | |
| SCHEMBL7178628 | 0.83 | MAPT (0.54) | MAPTKDM4EHPGDTP53ALDH1A1 | |
| SCHEMBL4936264 | 0.83 | MAPT (0.54) | MAPTKDM4EHPGDTP53ALDH1A1 | |
| SCHEMBL4936232 | 0.83 | MAPT (0.54) | MAPTKDM4EHPGDTP53ALDH1A1 | |
| SCHEMBL4938460 | 0.83 | MAPT (0.56) | MAPTKDM4EHPGDTP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080167318-A1 | Pharmaceutically active pyrrolidine derivatives | APPLIED RESEARCH SYSTEM ARS HOLDING N.V. (NL) | 2008-07-10 | — | — | US | disclosed |
| US-7211601-B2 | Pharmaceutically active pyrrolidine derivatives | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2007-05-01 | — | — | US | disclosed |
| EP-1268419-B1 | PYRROLIDINE DERIVATIVES USEFUL AS BAX INHIBITORS | APPLIED RESEARCH SYSTEMS (AN) | 2006-06-21 | — | — | EP | disclosed |
| EP-1268418-B1 | PHARMACEUTICALLY ACTIVE PYRROLIDINE DERIVATIVES AS BAX INHIBITORS | APPLIED RESEARCH SYSTEMS (AN) | 2006-06-14 | — | — | EP | disclosed |
| US-7018988-B2 | Pharmaceutically active pyrrolidine derivatives as Bax inhibitors | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2006-03-28 | — | — | US | disclosed |
| US-20030212012-A1 | Pharmaceutically active pyrrolidine derivatives | MERCK SERONO SA (CH) | 2003-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212012-A1 | Pharmaceutically active pyrrolidine derivatives | OXTR, CNR1, PRLHR | MAPT 4844/4885KDM4E 2553/4885HPGD 930/4885 |
| US-20080167318-A1 | Pharmaceutically active pyrrolidine derivatives | OXTR, PRLHR, NR0B1 | MAPT 4816/4885KDM4E 2451/4885HPGD 946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.